ARTICLE | Financial News

Lux Capital targeting $350M for new fund

February 12, 2015 2:23 AM UTC

Lux Capital has set a $350 million target for Lux Ventures IV, its new venture fund, according to an SEC filing. The firm, which invests in biotech and digital health as well as energy and high-tech, declined to comment on the filing.

The firm's life sciences investments include vaccine and immunotherapy company Genocea Biosciences Inc. (NASDAQ:GNCA); Cerulean Pharma Inc. (NASDAQ:CERU), which is developing nanoparticle-drug conjugates to treat cancer; ophthalmic company Kala Pharmaceuticals Inc. (Waltham, Mass.); and infectious disease play Visterra Inc. (Cambridge, Mass.). ...